Tiziana Life Sciences PLC Updated corporate presentation (8389M)
26 January 2021 - 6:00PM
UK Regulatory
TIDMTILS
RNS Number : 8389M
Tiziana Life Sciences PLC
26 January 2021
Updated corporate presentation
26 January 2021
New York/London, 26 January 2021 - Tiziana Life Sciences plc
(Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a
biotechnology company focused on innovative therapeutics for
oncology, inflammation, and infectious diseases, has today
published an updated presentation to its website at
https://ir.tizianalifesciences.com/presentation providing an update
with respect to an overview of its current clinical pipeline.
The presentation contains no new material information but gives
an overview of all of the Company's current and active development
pipeline, consolidating information the subject of previous
announcements, including the potential of Foralumab as a
lymphodepletion agent in CAR-T therapies for cancer.
The Company's budgeted expenditure for the full year 2021
remains $30m and budgeted expenditure for 2022 remains $28m; in
both cases the expenditure totals include all clinical and general
and administrative expenditure. Cash and cash equivalents as at
December 31, 2020 stood at US$62m.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA &
LSE: TILS) biotechnology company that focuses on the discovery and
development of novel molecules to treat human diseases in oncology,
inflammation and infectious diseases. In addition to milciclib, the
Company will be shortly initiating Phase 2 studies with orally
administered Foralumab for Crohn's Disease and nasally administered
Foralumab for progressive multiple sclerosis. Foralumab is the only
fully human anti-CD3 monoclonal antibody (mAb) in clinical
development in the world. This Phase 2 compound has potential
application in a wide range of autoimmune and inflammatory
diseases, such as Crohn's Disease, multiple sclerosis, type-1
diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and
rheumatoid arthritis, where modulation of a T-cell response is
desirable. The company is accelerating development of
anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal
antibody for treatment of IL6-induced inflammation, especially for
treatment of COVID-19 patients.
For further enquiries:
United Kingdom:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder
+44 (0)20 7495 2379
United States:
Investors:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
dave@redchip.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBAMBTMTATTFB
(END) Dow Jones Newswires
January 26, 2021 02:00 ET (07:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Nov 2023 to Nov 2024
